scispace - formally typeset
H

Harro Seelaar

Researcher at Erasmus University Rotterdam

Publications -  112
Citations -  11447

Harro Seelaar is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Frontotemporal dementia & Medicine. The author has an hindex of 25, co-authored 63 publications receiving 9260 citations. Previous affiliations of Harro Seelaar include Erasmus University Medical Center.

Papers
More filters
Journal ArticleDOI

FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.

TL;DR: The first comprehensive analysis of these FTLD-FUS cases is presented, in terms of neuropathology, genetics, demographics and clinical data, suggesting that the full complement of FTLD pathologies is yet to be elucidated.
Journal ArticleDOI

Distinct genetic forms of frontotemporal dementia.

TL;DR: Future genetic studies need to identify genetic defects in at least two distinct familial forms of frontotemporal dementia (FTD) with unknown genetic defects: frontotamporal lobe degeneration with ubiquitin-positive inclusions with hippocampal sclerosis and frontotmporal lobedegeneration with motor neuron disease.
Journal ArticleDOI

Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study.

Katrina M. Moore, +177 more
- 01 Feb 2020 - 
TL;DR: An international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72 to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried.
Journal ArticleDOI

Frequency of ubiquitin and FUS-positive, TDP-43-negative frontotemporal lobar degeneration.

TL;DR: The existence of this pathological subtype can be predicted with reasonable certainty by age at onset ≤40 years, negative family history, bvFTD and caudate atrophy on MRI, and the newly identified FTLD-FUS has a frequency of 11% inFTLD-U and an estimated frequency of three percent in the clinical FTD cohort.